Beijing Children’s Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)

  NCT07767253· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

  NCT07719140· Phase 4· Peking Union Medical College Hospital· Source

• Recruiting

  Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

  NCT07724756· Phase 2· Qilu Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Phase 3· Pfizer· Source

• Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Phase 3· Pfizer· Source

• Not yet recruiting

  A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

  NCT07106372· Phase 3· Keymed Biosciences Co.Ltd· Source

• Not yet recruiting

  A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis

  NCT07102888· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Active, not recruiting

  A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

  NCT07029711· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

  NCT06807268· Phase 3· Pfizer· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III

  NCT06971094· Phase 3· GeneCradle Inc· Source

• Not yet recruiting

  Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

  NCT06956196· Phase 3· Keymed Biosciences Co.Ltd· Source

• Recruiting

  An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

  NCT05066217· Phase 3· Epygenix· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· AbbVie· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Recruiting

  Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

  NCT06818916· Beijing Children's Hospital· Source

• Recruiting

  Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

  NCT07437404· Phase 3· Sinocelltech Ltd.· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05995353· Phase 3· AbbVie· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

  NCT05319353· Phase 3· Takeda· Source

• Recruiting

  Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

  NCT05906576· Phase 4· Taizhou Mabtech Pharmaceutical Co.,Ltd· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

• Active, not recruiting

  A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

  NCT05685238· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

  NCT05611801· Phase 3· Pfizer· Source

• Active, not recruiting

  A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

  NCT05330325· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

  NCT06417502· Peking Union Medical College Hospital· Source

• Recruiting

  A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

  NCT05334823· Phase 2· Chongqing Precision Biotech Co., Ltd· Source

• Active, not recruiting

  Pediatric Spinal Muscular Atrophy (SMA) China Registry

  NCT05042921· Biogen· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

  NCT04774718· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  NCT04589845· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

  NCT04462770· Phase 3· Epygenix· Source

• Active, not recruiting

  The Effectiveness and Safety of Resective Epilepsy Surgery for TRE

  NCT04198181· Beijing Children's Hospital· Source

• Active, not recruiting

  Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

  NCT02637687· Phase 1/2· Bayer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)4 recruiting
• Childhood cancers3 recruiting
• Crohn's disease3 recruiting
• Haemophilia3 recruiting
• Bronchiectasis2 recruiting
• Epilepsy2 recruiting
• Lupus (SLE)2 recruiting
• Psoriasis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alopecia areata1 recruiting
• Cytomegalovirus infection1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Spinal muscular atrophy1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Turner syndrome1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study

  NCT07249138· Children's Hospital of Fudan University· Source

• Completed

  Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

  NCT06738485· Phase 3· CSL Behring· Source

• Completed

  A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

  NCT06713499· Phase 1/2· Guangdong Hengrui Pharmaceutical Co., Ltd· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

  NCT06648772· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

  NCT06399289· Phase 3· CSL Behring· Source

• Completed

  Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

  NCT06324812· Phase 1/2· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

  NCT06162507· Phase 1/2· Keymed Biosciences Co.Ltd· Source

• Completed

  A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

  NCT05707351· Phase 3· Takeda· Source

• Completed

  Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China

  NCT05680298· Phase 4· Sanofi· Source

• Completed

  To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

  NCT05650320· Phase 3· Otsuka Beijing Research Institute· Source

• Completed

  A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

  NCT05529992· Phase 3· Takeda· Source

• Completed

  A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B

  NCT05365217· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

  NCT05306418· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Swedish Orphan Biovitrum· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Takeda· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Takeda· Source

• Completed

  Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

  NCT04737850· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

  NCT04565236· Phase 4· Bayer· Source

• Completed

  Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

  NCT03938792· Phase 3· Pfizer· Source

• Completed

  The Effectiveness and Safety of Vagus Nerve Stimulation for TRE

  NCT04198207· Beijing Children's Hospital· Source

• Recruiting

  A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

  NCT03773965· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study of Soticlestat in Adults and Children With Rare Epilepsies

  NCT03635073· Phase 2· Takeda· Source

• Completed

  Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

  NCT03315455· Phase 3· Hoffmann-La Roche· Source

• Completed

  Imaging of Arthropathy in Boys With Hemophilia in China

  NCT03914716· Andrea Doria· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Epilepsy41 works · 8 trials
• Neuroblastoma27 works · 2 trials
• Immune thrombocytopenia (ITP)22 works · 1 trial
• Atopic dermatitis (eczema)18 works · 13 trials
• Haemophilia15 works · 14 trials
• Tourette syndrome9 works · 0 trials
• Vitiligo7 works · 0 trials
• Alopecia areata6 works · 3 trials
• Spinal muscular atrophy6 works · 2 trials
• Dermatomyositis and polymyositis (myositis)4 works · 1 trial